You are here: Welcome to the MPKB » Welcome to the MPKB » Diseases
Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision		Previous revision
home:diseases [02.22.2019] – [Microbial communication] sallieqhome:diseases [09.14.2022] (current) – external edit 127.0.0.1
Line 9: Line 9:
 Some diseases are represented by more patients trying the therapy than others. As more patients join the MP cohort, the Autoimmunity Research Foundation will gather more data about the efficacy of the treatment with respect to individual diseases. In the meantime, the MP may be an appropriate treatment option for some of the diseases listed below.  Some diseases are represented by more patients trying the therapy than others. As more patients join the MP cohort, the Autoimmunity Research Foundation will gather more data about the efficacy of the treatment with respect to individual diseases. In the meantime, the MP may be an appropriate treatment option for some of the diseases listed below. 
  
-[[home:patients:patient_interviews|Approximately twenty patients]] have shared their stories of recovery on [[http://bacteriality.com/|Bacteriality.com]].+[[home:patients:patient_interviews|Many patients]] have shared their stories of recovery on [[https://www.marshallprotocol.com/|Marshall protocol study site]].
  
 ===== What is a chronic inflammatory disease? ===== ===== What is a chronic inflammatory disease? =====
Line 40: Line 40:
 ===== Microbial communication ===== ===== Microbial communication =====
  
- Here we show that an EHEC luxS mutant, unable to produce the bacterial autoinducer, still responds to a eukaryotic cell signal to activate expression of its virulence genes. We have identified this signal as the hormone epinephrine and show that β- and α-adrenergic antagonists can block the bacterial response to this hormone.  (({{pubmed>long:12847292}}))+ Here we show that an EHEC luxS mutant, unable to produce the bacterial autoinducer, still responds to a eukaryotic cell signal to activate expression of its virulence genes. We have identified this signal as the hormone epinephrine and show that β- and α-adrenergic antagonists can block the bacterial response to this hormone.  (({{pmid>long:12847292}}))
  
-The contribution of cell-cell signaling and motility to bacterial biofilm formation.  (({{pubmed>long:22053126}})) +The contribution of cell-cell signaling and motility to bacterial biofilm formation.  (({{pmid>long:22053126}}))
- +
- +
-Bacteria-triggered release of antimicrobial agents.  (({{pubmed>long:24288347 +
-}}))+
      
-  (({{pubmed>long:000}}))+Bacterial Biofilm Control by Perturbation of Bacterial Signaling Processes.(({{pmid>long:28902153}}))
      
-  (({{pubmed>long:000}}))+
  
 ===== List of diseases ===== ===== List of diseases =====
Line 67: Line 63:
  
    
 +<nodisp>
 ===== Notes and comments ===== ===== Notes and comments =====
  
Line 122: Line 119:
  
  
-<blockquote>Does Helicobater pylori infection play a role in extragastric diseases?{{pubmed>long:18249521}}+<blockquote>Does Helicobater pylori infection play a role in extragastric diseases?{{pmid>long:18249521}}
                  
          more options          more options
Line 155: Line 152:
  
 PMS: PMS:
-http://www.ncbi.nlm.nih.gov/pubmed/17468538?dopt=Abstract+https://www.ncbi.nlm.nih.gov/pubmed/17468538?dopt=Abstract
  
  
  
-<blockquote>I just got the all clear from CNS Vasculitis in less than 2 years and I would like that to show in the MPKB for the benefit of any Savvy vasculitis members who come across, I write periodically on the Savvy chat site about the protocol though I haven't seen any evidence of people taking notice except Lew newmark who wrote about it here:- http://mlcss.com/2010/10/13/the-keith-waterhouse-interview-part-three/+<blockquote>I just got the all clear from CNS Vasculitis in less than 2 years and I would like that to show in the MPKB for the benefit of any Savvy vasculitis members who come across, I write periodically on the Savvy chat site about the protocol though I haven't seen any evidence of people taking notice except Lew newmark who wrote about it here:- https://mlcss.com/2010/10/13/the-keith-waterhouse-interview-part-three/
 </blockquote> </blockquote>
  
Line 183: Line 180:
 <blockquote>From: Phillyguy <blockquote>From: Phillyguy
 Date: 2011-05-10 13:23:42 Date: 2011-05-10 13:23:42
-Reply: http://www.marshallprotocol.com/reply.php?topic_id=13412+Reply: https://www.marshallprotocol.com/reply.php?topic_id=13412
  
 Korean J Urol. 2011 vol. 52(3) pp. 194-9 Korean J Urol. 2011 vol. 52(3) pp. 194-9
Line 205: Line 202:
 From: ChrisMavo From: ChrisMavo
 Date: 2011-05-10 13:29:58 Date: 2011-05-10 13:29:58
-Reply: http://www.marshallprotocol.com/reply.php?topic_id=13412+Reply: https://www.marshallprotocol.com/reply.php?topic_id=13412
  
 Can someone explain what they mean by nanobacteria?  This is the first time I've seen this term used for bacteria.  Could this be the first indication of a whole new category of bacteria that has not been uncovered yet?  Are these nanobacteria the main component of what we call the microbiota? Can someone explain what they mean by nanobacteria?  This is the first time I've seen this term used for bacteria.  Could this be the first indication of a whole new category of bacteria that has not been uncovered yet?  Are these nanobacteria the main component of what we call the microbiota?
Line 216: Line 213:
 From: Bane From: Bane
 Date: 2011-05-10 14:14:45 Date: 2011-05-10 14:14:45
-Reply: http://www.marshallprotocol.com/reply.php?topic_id=13412+Reply: https://www.marshallprotocol.com/reply.php?topic_id=13412
  
 ChrisMavo wrote: Can someone explain what they mean by nanobacteria? ChrisMavo wrote: Can someone explain what they mean by nanobacteria?
Line 224: Line 221:
  
  
-http://tiny.cc/1lxnw+https://tiny.cc/1lxnw
  
 </blockquote> </blockquote>
Line 232: Line 229:
 High levels of Epstein–Barr virus in COPD High levels of Epstein–Barr virus in COPD
  
-http://erj.ersjournals.com/content/31/6/1221.long+https://erj.ersjournals.com/content/31/6/1221.long
  
  
Line 253: Line 250:
  
  
-http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2854762/+https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2854762/
  
  
Line 279: Line 276:
  
 From: LeeDate: 2011-11-01 07:44:01 From: LeeDate: 2011-11-01 07:44:01
-Reply: http://www.marshallprotocol.com/reply.php?topic_id=13718+Reply: https://www.marshallprotocol.com/reply.php?topic_id=13718
  
  
Line 292: Line 289:
 From: eClaire From: eClaire
 Date: 2011-11-01 11:07:07 Date: 2011-11-01 11:07:07
-Reply: http://www.marshallprotocol.com/reply.php?topic_id=13718+Reply: https://www.marshallprotocol.com/reply.php?topic_id=13718
  
  
Line 311: Line 308:
 PMID: 21376827  PMID: 21376827 
  
-</blockquote>+</blockquote></nodisp> 
home/diseases.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.